These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23909028)

  • 41. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
    Ganesan S; Karantza V; Oza J; Toppmeyer D
    Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significance of biomarker discordance in breast cancer from the pathologist's perspective.
    Gong Y
    Cancer Biomark; 2012-2013; 12(6):207-18. PubMed ID: 23735941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.
    Reuben JM; Lee BN; Li C; Gao H; Broglio KR; Valero V; Jackson SA; Ueno NT; Krishnamurthy S; Hortobagyi GN; Cristofanilli M
    Breast J; 2010; 16(3):327-30. PubMed ID: 20408820
    [No Abstract]   [Full Text] [Related]  

  • 46. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
    Giatromanolaki A; Koukourakis MI; Simopoulos C; Polychronidis A; Gatter KC; Harris AL; Sivridis E
    Clin Cancer Res; 2004 Dec; 10(23):7972-7. PubMed ID: 15585632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coming of age: breast cancer in seniors.
    Muss HB
    Oncologist; 2011; 16 Suppl 1():79-87. PubMed ID: 21278444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 51. Quadruple negative breast cancer.
    Huang M; Wu J; Ling R; Li N
    Breast Cancer; 2020 Jul; 27(4):527-533. PubMed ID: 31939077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.
    Schiavon G; Tait DM; Briggs TW; Smith IE
    Clin Breast Cancer; 2013 Feb; 13(1):77-80. PubMed ID: 23199805
    [No Abstract]   [Full Text] [Related]  

  • 54. Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients.
    Altundag K
    J BUON; 2019; 24(5):2206. PubMed ID: 31786897
    [No Abstract]   [Full Text] [Related]  

  • 55. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 56. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.
    Fitzgibbons PL; Dillon DA; Alsabeh R; Berman MA; Hayes DF; Hicks DG; Hughes KS; Nofech-Mozes S
    Arch Pathol Lab Med; 2014 May; 138(5):595-601. PubMed ID: 24236805
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of the androgen receptor in triple-negative breast cancer.
    Shah PD; Gucalp A; Traina TA
    Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?
    Amir E; Clemons M
    Lancet Oncol; 2009 Oct; 10(10):933-5. PubMed ID: 19796747
    [No Abstract]   [Full Text] [Related]  

  • 59. Epigenetic inactivation of DNA repair in breast cancer.
    Nowsheen S; Aziz K; Tran PT; Gorgoulis VG; Yang ES; Georgakilas AG
    Cancer Lett; 2014 Jan; 342(2):213-22. PubMed ID: 22634493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?
    Johnston SR
    J Clin Oncol; 2016 Feb; 34(5):393-5. PubMed ID: 26700117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.